Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

PHASE III SAFETY EVALUATION OF CYCLOSPORINE 0.1% OPHTHALMIC EMULSION ADMINISTERED TWICE DAILY TO DRY EYE DISEASE PATIENTS FOR UP TO 3 YEARS

Cohen, Elisabeth J. MD

Evidence-Based Ophthalmology: October 2006 - Volume 7 - Issue 4 - p 172-173
doi: 10.1097/01.ieb.0000212037.20074.70
CLINICAL STUDIES
Buy

Wills Eye Hospital Philadelphia, PA

Original study reprint requests: Laurie D. Barber, MD, Department of Ophthalmology, University of Arkansas for Medical Sciences No. 523, Little Rock, AR 72205.

© 2006 Lippincott Williams & Wilkins, Inc.